BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 12886055)

  • 1. Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study.
    Yang TS; Chen JS; Tang R; Chiang JM; Hsieh PS; Yeh CY; Changchien CR
    Chemotherapy; 2003 Jul; 49(4):194-9. PubMed ID: 12886055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
    J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
    Kalofonos HP; Papakostas P; Makatsoris T; Papamichael D; Vourli G; Xanthakis I; Aravantinos G; Papadimitriou C; Pentheroudakis G; Varthalitis I; Samelis G; Syrigos KN; Xiros N; Stavropoulos M; Kosmidis P; Christodoulou C; Linardou H; Skondra M; Pectasides D; Economopoulos T; Fountzilas G
    Anticancer Res; 2010 Oct; 30(10):4325-33. PubMed ID: 21036759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
    Cassinello J; Escudero P; Salud A; Marcos F; Pujol E; Pérez-Carrión R; Colmenarejo A; González del Val R; Valero J; Oruezábal MJ; Guillem V; García I; Arcediano A; Marfà X
    Clin Colorectal Cancer; 2003 Aug; 3(2):108-12. PubMed ID: 12952567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
    Souglakos J; Mavroudis D; Kakolyris S; Kourousis Ch; Vardakis N; Androulakis N; Agelaki S; Kalbakis K; Tsetis D; Athanasiadis N; Samonis G; Georgoulias V
    J Clin Oncol; 2002 Jun; 20(11):2651-7. PubMed ID: 12039926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study.
    Kouroussis C; Souglakos J; Kakolyris S; Mavroudis D; Malamos N; Kalbakis K; Androulakis N; Agelaki A; Vardakis N; Samonis G; Georgoulias V
    Oncology; 2001; 61(1):36-41. PubMed ID: 11474246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
    Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
    J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biweekly bolus 5-fluorouracil and leucovorin plus oxaliplatin in pretreated patients with advanced colorectal cancer: a dose-finding study.
    Yang TS; Chen JS; Tang R; Chiang JM; Hsieh PS; Yeh CY; Changchien CR
    Anticancer Drugs; 2003 Feb; 14(2):145-51. PubMed ID: 12569301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
    Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
    Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.
    Hegewisch-Becker S; Gruber Y; Corovic A; Pichlmeier U; Atanackovic D; Nierhaus A; Hossfeld DK
    Ann Oncol; 2002 Aug; 13(8):1197-204. PubMed ID: 12181242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
    Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
    Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens.
    Hsieh RK; Chao TY; Chen WS; Yang TS; Chen LT; Chen PM; Liu JH
    Cancer Invest; 2004; 22(2):171-9. PubMed ID: 15199598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
    Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
    Kalofonos HP; Aravantinos G; Kosmidis P; Papakostas P; Economopoulos T; Dimopoulos M; Skarlos D; Bamias A; Pectasides D; Chalkidou S; Karina M; Koutras A; Samantas E; Bacoyiannis C; Samelis GF; Basdanis G; Kalfarentzos F; Fountzilas G
    Ann Oncol; 2005 Jun; 16(6):869-77. PubMed ID: 15855226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
    Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Gilles V; Lotz JP; Tournigand C; Mabro M; Molitor JL; Artru P; Izrael V; Krulik M
    Ann Oncol; 2000 Nov; 11(11):1477-83. PubMed ID: 11142489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.
    de Gramont A; Vignoud J; Tournigand C; Louvet C; André T; Varette C; Raymond E; Moreau S; Le Bail N; Krulik M
    Eur J Cancer; 1997 Feb; 33(2):214-9. PubMed ID: 9135491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.